GSK’s Veramyst fluticasone furoate nasal spray will soon be available as an over-the-counter product marketed as Flonase Sensimist, GSK Consumer Healthcare has announced. According to the company, the FDA has approved Flonase Sensimist as an OTC treatment for seasonal and allergic rhinitis symptoms. Veramyst was initially approved in 2007.
GSK Consumer Healthcare Director of Marketing Amardeep Kahlon commented, “There are roughly 50 million people in the United States who suffer from allergies and, as a category leader, GSK continues to innovate to satisfy the needs of all allergy sufferers. In the case of Flonase Sensimist, GSK is proud to offer an additional treatment option that not only provides more complete allergy symptom relief1 but also suits specific consumer preferences.”
Flonase Sensimist is expected to be available OTC throughout the US early in 2017. Flonase fluticasone propionaate nasal spray has been available over the counter in the US since February 2015.
Read the GSK press release.
